The effects of ciprofloxacin on chest radiographic regression in patients with drug intolerance or resistant tuberculosis

Chao Kai Yang, Horng Chyuan Lin, Kang Yun Lee, Shu Min Lin, Chih Teng Yu, Han Pin Kuo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The aim of this study was to identify the clinical efficacy of ciprofloxacin as a second-line anti-tuberculosis agent in pulmonary tuberculosis patients with drug intolerance or resistance. Methods: There were 20 patients with drug related adverse effects or drug resistance enrolled in the ciprofloxacin treatment group (CG). There were also 32 patients enrolled in the non-ciprofloxacin treatment group (NCG) that maintained conventional drug regimens or the addition of other drugs like streptomycin. The radiographic presentation was evaluated using score grading. The speed and outcome of regression in the chest radiographic presentations were also evaluated. Results: Data showed the CG had significantly more rapid regression than the NCG in drug-resistant patients (p <0.01). For the adversely effected patients in the CG, the mean scores of pre- and post-treatment were 3.1 ± 0.2 and 2.2 ± 0.3 (p <0.001), respectively. For the adversely effected patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.4 and post-treatment mean score was 3.0 ± 0.4 (p <0.05). For the drug-resistant patients in the CG, the mean scores of pre- and post-treatment were 4.3 ± 0.4 and 3.4 ± 0.5 (p <0.05), respectively. For the drug-resistant patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.3 and post-treatment mean score was 3.2 ± 0.3 (no significant difference). Obviously, the CG had the same effects compared with the NCG in adverse-effect group. On the other hand, the CG had the tendency of more rapid radiographic regression and better radiographic outcomes than the NCG in drug-resistant patients. Conclusions: Ciprofloxacin provides a better option for second-line drug treatment for pulmonary tuberculosis when patients cannot use conventional anti-tuberculosis agents.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalChang Gung Medical Journal
Volume27
Issue number4
Publication statusPublished - Apr 2004
Externally publishedYes

Fingerprint

Ciprofloxacin
Tuberculosis
Thorax
Pharmaceutical Preparations
Therapeutics
Pulmonary Tuberculosis

Keywords

  • Ciprofloxacin
  • Drug intolerance
  • Drug resistance
  • Pulmonary tuberculosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effects of ciprofloxacin on chest radiographic regression in patients with drug intolerance or resistant tuberculosis. / Yang, Chao Kai; Lin, Horng Chyuan; Lee, Kang Yun; Lin, Shu Min; Yu, Chih Teng; Kuo, Han Pin.

In: Chang Gung Medical Journal, Vol. 27, No. 4, 04.2004, p. 292-299.

Research output: Contribution to journalArticle

@article{525f0037cc92425793b7dd34f4f1b745,
title = "The effects of ciprofloxacin on chest radiographic regression in patients with drug intolerance or resistant tuberculosis",
abstract = "Background: The aim of this study was to identify the clinical efficacy of ciprofloxacin as a second-line anti-tuberculosis agent in pulmonary tuberculosis patients with drug intolerance or resistance. Methods: There were 20 patients with drug related adverse effects or drug resistance enrolled in the ciprofloxacin treatment group (CG). There were also 32 patients enrolled in the non-ciprofloxacin treatment group (NCG) that maintained conventional drug regimens or the addition of other drugs like streptomycin. The radiographic presentation was evaluated using score grading. The speed and outcome of regression in the chest radiographic presentations were also evaluated. Results: Data showed the CG had significantly more rapid regression than the NCG in drug-resistant patients (p <0.01). For the adversely effected patients in the CG, the mean scores of pre- and post-treatment were 3.1 ± 0.2 and 2.2 ± 0.3 (p <0.001), respectively. For the adversely effected patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.4 and post-treatment mean score was 3.0 ± 0.4 (p <0.05). For the drug-resistant patients in the CG, the mean scores of pre- and post-treatment were 4.3 ± 0.4 and 3.4 ± 0.5 (p <0.05), respectively. For the drug-resistant patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.3 and post-treatment mean score was 3.2 ± 0.3 (no significant difference). Obviously, the CG had the same effects compared with the NCG in adverse-effect group. On the other hand, the CG had the tendency of more rapid radiographic regression and better radiographic outcomes than the NCG in drug-resistant patients. Conclusions: Ciprofloxacin provides a better option for second-line drug treatment for pulmonary tuberculosis when patients cannot use conventional anti-tuberculosis agents.",
keywords = "Ciprofloxacin, Drug intolerance, Drug resistance, Pulmonary tuberculosis",
author = "Yang, {Chao Kai} and Lin, {Horng Chyuan} and Lee, {Kang Yun} and Lin, {Shu Min} and Yu, {Chih Teng} and Kuo, {Han Pin}",
year = "2004",
month = "4",
language = "English",
volume = "27",
pages = "292--299",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "4",

}

TY - JOUR

T1 - The effects of ciprofloxacin on chest radiographic regression in patients with drug intolerance or resistant tuberculosis

AU - Yang, Chao Kai

AU - Lin, Horng Chyuan

AU - Lee, Kang Yun

AU - Lin, Shu Min

AU - Yu, Chih Teng

AU - Kuo, Han Pin

PY - 2004/4

Y1 - 2004/4

N2 - Background: The aim of this study was to identify the clinical efficacy of ciprofloxacin as a second-line anti-tuberculosis agent in pulmonary tuberculosis patients with drug intolerance or resistance. Methods: There were 20 patients with drug related adverse effects or drug resistance enrolled in the ciprofloxacin treatment group (CG). There were also 32 patients enrolled in the non-ciprofloxacin treatment group (NCG) that maintained conventional drug regimens or the addition of other drugs like streptomycin. The radiographic presentation was evaluated using score grading. The speed and outcome of regression in the chest radiographic presentations were also evaluated. Results: Data showed the CG had significantly more rapid regression than the NCG in drug-resistant patients (p <0.01). For the adversely effected patients in the CG, the mean scores of pre- and post-treatment were 3.1 ± 0.2 and 2.2 ± 0.3 (p <0.001), respectively. For the adversely effected patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.4 and post-treatment mean score was 3.0 ± 0.4 (p <0.05). For the drug-resistant patients in the CG, the mean scores of pre- and post-treatment were 4.3 ± 0.4 and 3.4 ± 0.5 (p <0.05), respectively. For the drug-resistant patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.3 and post-treatment mean score was 3.2 ± 0.3 (no significant difference). Obviously, the CG had the same effects compared with the NCG in adverse-effect group. On the other hand, the CG had the tendency of more rapid radiographic regression and better radiographic outcomes than the NCG in drug-resistant patients. Conclusions: Ciprofloxacin provides a better option for second-line drug treatment for pulmonary tuberculosis when patients cannot use conventional anti-tuberculosis agents.

AB - Background: The aim of this study was to identify the clinical efficacy of ciprofloxacin as a second-line anti-tuberculosis agent in pulmonary tuberculosis patients with drug intolerance or resistance. Methods: There were 20 patients with drug related adverse effects or drug resistance enrolled in the ciprofloxacin treatment group (CG). There were also 32 patients enrolled in the non-ciprofloxacin treatment group (NCG) that maintained conventional drug regimens or the addition of other drugs like streptomycin. The radiographic presentation was evaluated using score grading. The speed and outcome of regression in the chest radiographic presentations were also evaluated. Results: Data showed the CG had significantly more rapid regression than the NCG in drug-resistant patients (p <0.01). For the adversely effected patients in the CG, the mean scores of pre- and post-treatment were 3.1 ± 0.2 and 2.2 ± 0.3 (p <0.001), respectively. For the adversely effected patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.4 and post-treatment mean score was 3.0 ± 0.4 (p <0.05). For the drug-resistant patients in the CG, the mean scores of pre- and post-treatment were 4.3 ± 0.4 and 3.4 ± 0.5 (p <0.05), respectively. For the drug-resistant patients in the NCG, the mean score of pre-treatment was 3.7 ± 0.3 and post-treatment mean score was 3.2 ± 0.3 (no significant difference). Obviously, the CG had the same effects compared with the NCG in adverse-effect group. On the other hand, the CG had the tendency of more rapid radiographic regression and better radiographic outcomes than the NCG in drug-resistant patients. Conclusions: Ciprofloxacin provides a better option for second-line drug treatment for pulmonary tuberculosis when patients cannot use conventional anti-tuberculosis agents.

KW - Ciprofloxacin

KW - Drug intolerance

KW - Drug resistance

KW - Pulmonary tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=3042699975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042699975&partnerID=8YFLogxK

M3 - Article

C2 - 15239196

AN - SCOPUS:3042699975

VL - 27

SP - 292

EP - 299

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 4

ER -